Who
Mark K. Oki
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Achieve Life Sciences; Chief Financial Officer, Aytu BioPharma; Chief Financial Officer & CAO, Vivus; SVP, Finance, CFO & Sec, Alexza Pharmaceuticals.
In numbers
- Trades disclosed
- 47
- Buys
- 3
- Sells
- 3
- Bought
- $90K
- Sold
- $198K
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 22 Feb 2011
- Last trade
- 28 Jan 2026
- Last filed
- 30 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Jan 2026filed 30 Jan 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 28 Jan 2026filed 30 Jan 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 18 Sep 2025filed 22 Sep 2025 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —168,000 at $0.00 | filing |
| 18 Sep 2025filed 22 Sep 2025 | ACHV Achieve Life SciencesDiagnostics & Labs | SEC FORM 4 Code M | —168,000 at $0.00 | filing |
| 18 Sep 2025filed 22 Sep 2025 | ACHV Achieve Life SciencesDiagnostics & Labs | SEC FORM 4 Sold | $146K50,060 at $2.92 | filing |
| 4 Sep 2025filed 8 Sep 2025 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —168,000 at $0.00 | filing |
| 17 Mar 2025filed 19 Mar 2025 | ACHV Achieve Life SciencesDiagnostics & Labs | SEC FORM 4 Bought | $29K10,000 at $2.89 | filing |
| 6 Dec 2024filed 9 Dec 2024 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —72,000 at $0.00 | filing |
| 6 Dec 2024filed 9 Dec 2024 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —168,000 at $0.00 | filing |
| 11 Aug 2023filed 15 Aug 2023 | AYTU Aytu BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 18 Nov 2022filed 28 Nov 2022 | AYTU Aytu BioPharmaBiotechnology | SEC FORM 4 Bought | $21K90,000 at $0.23 | filing |
| 18 Nov 2022filed 21 Nov 2022 | AYTU Aytu BioPharmaBiotechnology | SEC FORM 4 Code A | $21K90,000 at $0.23 | filing |
| 17 Jan 2022filed 19 Jan 2022 | AYTU Aytu BioPharmaBiotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 29 Jan 2020filed 31 Jan 2020 | Vivusoption or derivative | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 14 Nov 2019filed 18 Nov 2019 | Vivus | SEC FORM 4 Code A | $1,666700 at $2.38 | filing |
| 14 May 2019filed 15 May 2019 | Vivus | SEC FORM 4 Code A | $1,988700 at $2.84 | filing |
| 23 Jan 2019filed 25 Jan 2019 | Vivusoption or derivative | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 14 Nov 2018filed 16 Nov 2018 | Vivus | SEC FORM 4 Code A | $1,897700 at $2.71 | filing |
| 6 Nov 2018filed 7 Nov 2018 | Vivus | SEC FORM 4 Bought | $41K10,000 at $4.07 | filing |
| 30 Apr 2018filed 2 May 2018 | Vivusoption or derivative | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
News
Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and CommunicationsACHV · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Mark K. Oki; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.